PTC Therapeutics enters into a global license and collaboration agreement with Novartis for PTC518 Huntington's disease program
- PTC Therapeutics will receive $1 billion upfront and up to $1.9 billion in milestones from Novartis.
- The agreement includes a profit share in the U.S. and tiered double-digit royalties on ex-U.S. sales.
- Novartis will handle global development, manufacturing, and commercialization after the PIVOT-HD study.
- The transaction is expected to close in the first quarter of 2025, pending regulatory clearance.
Read more
